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Abstract Although essential for cell physiology, an in-
crease or depletion of body iron has harmful effects on
health. Apart from iron deficiency anemia and iron
overload-related organ tissue damage, there are increasing
evidences that body iron status is implicated in atheroscle-
rotic cardiovascular diseases. The hypothesis formulated in
1981 that iron depletion may protect against cardiovascular
events is intriguing and has generated a significant debate
in the last two decades. Indeed, to study this phenomenon,
several investigators have tried to design appropriate
experimental and clinical studies and to identify useful
biochemical and genetic markers of iron status. The results
of the literature on the effect of iron deficiency and
overload on vascular health are critically reviewed in this
study from a pathogenic and clinical point of view.
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Introduction
Iron is an essential nutrient for living cells because of its
role as a cofactor for enzymes in the mitochondrial
respiration chain, in the DNA synthesis, and being the
central molecule for binding and transport of oxygen by
hemoglobin and myoglobin.
While the lack of iron leads to growth arrest and anemia,
an increased accumulation of this metal is associated with
toxic radical formation and progressive tissue damage. It is
interesting to note that both iron deficiency and excess have
been associated with an increased risk of developing
thromboembolic events [1–7].
This review will analyze, from a clinical and pathogenic
point of view, the existing literature data on the relationship
between iron and arterial and venous thrombosis.
Iron deficiency and thrombosis
There are several reports in the literature on thrombotic
complications in iron-deficient children and adults [8–26].
Secondary thrombocytosis has been implicated in many
cases. Indeed, iron deficiency is a cause of reactive
thrombocytosis, usually mild [27]. For instance, within a
study group of children with iron deficiency, reactive
thrombocytosis was found in up to one-third of them [28].
Nagai et al. [29] reported a case of severe iron deficiency
with marked thrombocytosis (1,020×10
9/l) that was com-
plicated by central retinal vein occlusion. By contrast,
Kinoshita et al. [26] described two cases of cerebral venous
sinus thrombosis associated with iron deficiency and
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e-mail: mfranchini@univr.itnormal platelet count. Hartfield et al. [13] reported six
children with iron deficiency who developed an ischemic
stroke or venous thrombosis. Four of them had a concom-
itant thrombocytosis. In a prospective case–control study,
Stolz et al. [30] found that severe anemia, along with
thrombophilia and hypercholesterolemia, were independent
risk factors for cerebral venous thrombosis.
The mechanisms causing reactive thrombocytosis in iron
deficiency anemia are not completely understood. Iron is an
important regulator of thrombopoiesis [31, 32]. Whereas
normal iron levels are required to prevent thrombocytosis
by inhibiting thrombopoiesis, a minimum amount of iron is
required to maintain platelet production. Thus, while
thrombocytosis is usually associated with a mild iron
deficiency and is the result of a lack of inhibition of
thrombopoiesis, a severe defect of this metal may be
accompanied by thrombocytopenia. However, studies on
thrombopoietic cytokines failed to show any effect on
reactive thrombocytosis in iron deficiency [27]. For
instance, Akan et al. [33] assayed the serum levels of
thrombopoietin, erythropoietin, leukemia inhibitor factor,
IL-6, and IL-11 in patients with iron-deficient anemia with
or without elevated platelet count. Only erythropoietin level
was elevated, correlated with thrombocytosis, and de-
creased with iron replacement. The other cytokines
remained unchanged after therapy, suggesting that they
probably do not play any significant role in iron deficiency-
associated reactive thrombocytosis. Recently, Bilic and
Bilic reported that the amino acid sequence homology of
thrombopoietin and erythropoietin may explain the throm-
bocytosis in children with iron deficiency anemia [34]. By
contrast, two other reports suggested that the relationship
between iron deficiency and reactive thrombocytosis is
more complex than a mere consequence of a crossreactivity
between erythropoietin and thrombopoietin [35, 36]. In
addition to the increased thrombotic risk associated with
high platelet count, other authors have suggested that the
decrease in antioxidant defense in iron deficiency anemia
may cause increased oxidant stress, which in turn may
result in a tendency toward platelet aggregation [37]. Thus,
the abnormal platelet count and function observed in iron
deficiency anemia could act synergistically to promote
thrombus formation, especially in the setting of an
underlying atherosclerotic disease [23].
However, as not all cases of iron-related thrombotic
events occur in patients with concomitant high platelet
count [13, 26], other pathogenic mechanisms have been
proposed in these last years. Thus, iron deficiency may
contribute to a hypercoagulable state by affecting blood
flow patterns within the vessels because of reduced
deformability and increased viscosity of microcytic red
blood cells [13]. Furthermore, anemic hypoxia secondary to
iron deficiency could precipitate situations of increased
metabolic stress (i.e., infections) in particularly vulnerable
areas of the brain supplied by end arteries, such as the basal
ganglia, thalamus, and hypothalamus [38]. This phenome-
non could explain the association between iron-deficient
anemia and reversible focal deficits and stroke found by
some authors [1, 13, 39, 40].
Iron overload and thrombosis
Accumulation of iron in excess of physiologic requirements
has been implicated in the development of several chronic
illnesses, including cardiovascular diseases [7]. As previ-
ously reported, iron is a prooxidant cofactor associated with
an increased production of hydroxyl radical in cardiovas-
cular tissues and increased progression of atherosclerosis in
experimental models [41–44]. Indeed, in an experimental
mouse thrombosis model, a moderate iron overload
markedly accelerated thrombus formation, impaired vaso-
reactivity, and enhanced the production of reactive oxygen
species and systemic markers of oxidative stress [41]. It is
interesting to note that the administration of DL-cysteine, a
reactive oxygen species scavenger, completely abrogated
the iron load-induced thrombus formation thus corroborat-
ing the hypothesis that iron accelerates thrombosis through
a prooxidant mechanism. Similarly, laboratory investiga-
tions have demonstrated iron-dependent generation of
reactive oxygen species in endothelial cell cultures and
increased aortic atherosclerosis in the apolipoprotein E-
deficient mice and cholesterol-fed rabbits with increased
iron intake [42–44].
The research in this field has focused on the evaluation
of the impact of iron depletion and iron overload on
cardiovascular outcomes. Sullivan first postulated in 1981
the “iron hypothesis” by which the chronic iron depletion
has a protective effect against ischemic heart disease and
may account for the reduced risk of cardiovascular events
in menstruating women [45–47]. Basing on these observa-
tions, some investigators have studied the effect of serial
blood donations on the coronary heart disease risk, but their
results were inconsistent [48–53]. However, an important
support to the hypothesis of a potential link between blood
donation and reduced cardiovascular risk came from a
recent study conducted by Zheng et al. [54] who found that
high-frequency blood donors had decreased serum ferritin
levels, a marker of body iron stores; decreased serum 3-
nitrotyrosine levels, a marker of oxidative stress; and
greater flow-mediated dilation in the brachial artery, a
marker of vascular function. It is interesting to note that in a
clinical study, the iron chelation with deferoxamine
improved endothelial function in patients with coronary
artery disease [55]. By contrast, in a multicenter, random-
ized controlled trial (the iron [Fe] and Atherosclerosis
168 Ann Hematol (2008) 87:167–173Study [FeAST]) on 1,277 patients with symptomatic
peripheral arterial disease, the reduction of body iron stores
by phlebotomy did not significantly decrease all-cause
mortality or death plus nonfatal myocardial infarction and
stroke [56]. Similarly, in a prospective analysis of the
second National Health and Nutrition Examination Study
(NHANES II), Sempos et al. [57] observed either no
association (in Caucasian men) or a possible nonsignificant
increased risk (in Caucasian women) of cardiovascular or
coronary heart disease death among individuals with low
ferritin concentrations.
On the other hand, the association between biochemical
markers of body iron load and the risk of developing
cardiovascular disease have been investigated by several
studies [7, 58–72]. In the Kuopio Ischemic Heart Disease
Risk Factor Study (KIHD), serum ferritin levels were found
to be one of the strongest risk factors for acute myocardial
infarction among Finnish men [61]. Similar findings were
reported from a Canadian study [65] that observed an
increased risk of myocardial infarction among subjects in
the highest serum iron category and from the Bruneck study
[64] in which a positive association between serum ferritin
levels and ultrasound measures of progression of carotid
atherosclerosis over a 5-year follow-up period was found. A
relationship between serum ferritin levels and carotid
atherosclerosis was also identified by a recent study
conducted by Wolff et al. [71]. Haidari et al. [60] observed
a significant correlation between serum ferritin levels and
risk of coronary heart disease in male Iranian patients.
However, a number of epidemiological studies did not find
an association between iron status and coronary artery
disease [61, 69, 70, 72]. For instance, Bozzini et al. [61]
found that the mean serum ferritin concentrations were
slightly higher in coronary heart disease patients than in
controls, but this difference disappeared after adjusting for
sex and C-reactive protein.
The 1996 discovery of HFE gene mutations responsible
for most cases of hereditary hemochromatosis has led to the
use of genetic markers of iron overload, which are not
influenced by external factors such as inflammation, in
epidemiologic studies. Thus, several authors have investi-
gated in recent years the relationship between C282Y and
H63D mutations in the HFE gene and the risk of
cardiovascular diseases [73–88]. Three prospective popula-
tion-based studies have reported an association between
heterozygotes and vascular events [75–77].
The first study was from a subgroup of the original
Finnish KIHD cohort [75]. Of 68 individuals, 8 (11.8%)
were diagnosed with acute myocardial infarction, and of
1,150 noncoronary heart disease participants, 77 (6.7%)
Table 1 Summary of the most important studies on the association between HFE gene mutations (C282Y and H63D) and the risk of
cardiovascular diseases
Authors [reference] Study design Population Results
Tuomainen et al.
[75]
Prospective 1,150 individuals C282Y heterozygosity is associated with a 2.3 RR
for AMI compared with noncarriers
Roest et al.
[76]
Prospective 12,239 postmenopausal women C282Y heterozygosity is associated with a 1.6 RR
for TCD compared with noncarriers
Rasmussen et al.
[77]
Prospective 243 CHD cases and 535 controls C282Y heterozygosity is associated with a 2.7 RR
for CHT compared with noncarriers
Gaenzer et al.
[78]
Case–control 41 C282Y/C282Y cases and 51 controls C282Y homozygosity is associated with impaired
endothelial function
Bozzini et al.
[61]
Case–control 546 CHD cases and 303 controls C282Y mutation is not associated with CHD
Rossi et al.
[80]
Case–control 1,098 subjects C282Y mutation is not a risk factor for
asymptomatic carotid atherosclerosis
Franco et al.
[81]
Case–control 256 CHD cases and 272 controls C282Y and H63D mutations are not associated
with CHD
Ellervik et al.
[79]
Prospective 9,178 individuals C282Y and H63D mutations are not associated
with CHD
Case–control 2,441 CHD and 1,113 AMI cases
vs 8,080 controls
C282Y and H63D mutations are not associated
with CHD
Gunn et al.
[86]
Case–control 482 CHD cases and 1,104 controls C282Y mutation is not associated with CHD
Campbell et al.
[88]
Case–control 924 AMI cases and 1,029 controls C282Y mutation is not associated with CHD
Yunker et al.
[89]
Case–control 907 individuals HFE genotype is not related to brachial endothelial
function and carotid atherosclerosis
AMI: acute myocardial infarction, CHD: coronary heart disease, RR: relative risk, TCD: total cardiovascular death
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myocardial infarction was 2.0 (95%CI=0.9–4.1) and the
adjusted relative risk was 2.3 (95%CI=1.1–4.8). In a cohort
of 12,239 Dutch postmenopausal women, the C282Y
carrier status was assessed among 531 women who died
of cardiovascular disease and 555 randomly selected
women who did not die of cardiovascular disease [76].
This study reported a relative risk of 1.6 (95%CI=1.1–2.4)
for total cardiovascular death. Finally, in the United States
Atherosclerosis Risk in Communities (ARIC) study [77], a
C282Y carrier frequency of 9.9% among 243 coronary
heart disease cases and 6.1% among 535 controls was
reported. The crude relative risk of coronary heart disease
associated with C282Y carrier status was 1.6 (95%CI=0.9–
3.0) and was 2.7 (95%CI=1.2–6.0) after being controlled
for other risk factors. To support of these findings, Gaenzer
et al. [78] found an association between increased iron
stores and impaired endothelial function (measured as
endothelium-dependent dilation and intima-media thick-
ness) in patients homozygous for C282Y mutation. Iron-
depletion therapy normalized the endothelial function in
such patients thus reducing the increased risk of cardiovas-
cular events.
However, the majority of the studies disagreed with
these results [61, 79–89]. Indeed, Bozzini et al. [61] found a
similar rate of carriers of C282Y mutation among patients
with coronary atherosclerotic disease and controls. In a
case–control study on 1,098 subjects, Rossi et al. [80]
found that C282Y mutation was not a predictor of
asymptomatic carotid atherosclerosis. Franco et al. [81]
reported that the HFE genes were not associated with
coronary or peripheral atherosclerosis in patients aged less
than 50 years. Similarly, in the West of Scotland Coronary
Prevention Study (WOSCOPS), Gunn et al. [86] found that
the presence of a C282Y mutation in the HFE gene did not
predict the occurrence of coronary events over a mean
follow-up of 4.9 years. It is interesting to note that Yunker
et al. [89] analyzed the relationship between biochemical
and genetic markers of iron overload and carotid intima-
media thickness and brachial flow-mediated vasodilation by
high-resolution ultrasound in 907 males, but neither ferritin
nor hemochromatosis genotype were related to brachial
endothelial function and carotid atherosclerosis. In addition,
a recent large study from Denmark found no increased risk
of coronary heart disease among carriers of the C282Y
mutation or individuals who had compound heterozygosity
for the C282Y and H63D mutations [79].
Other investigation have focused on the association
between genetic markers of iron overload and idiopathic
dilated cardiomyopathy and stroke, but their results were
conflicting [90–94].
Finally, some authors have suggested that HFE C282Y
could interact with other predisposing factors for venous
thromboembolism, such as factor V Leiden, thus exacer-
bating their prothrombotic effect [95].
Table 1 summarizes the most important studies on the
association between genetic markers of iron overload and
cardiovascular diseases.
Conclusions
It is interesting to note that although with different
pathogenic mechanisms, both iron deficiency and overload
have been associated with an increased thrombotic risk in
experimental and clinical studies.
However, several aspects need to be still elucidated in
this field. In particular, large prospective controlled trials
are needed to elucidate the role of genetic markers of iron
stores and the impact of long-term iron depletion on
morbidity and mortality from cardiovascular events.
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